Skip to main content
Premium Trial:

Request an Annual Quote

Brett Hall

Molecular Response announced that Brett Hall will be its new CEO and will lead the firm's repositioning as a drug development company. As Molecular Response Therapeutics, the firm will develop treatments that interrogate tumor cell interactions "with permissive host tumor microenvironments," the company said in a statement. 

Hall previously led the oncology translational medicine group within AstraZeneca subsidiary MedImmune. Before that, he was in charge of the hematologic oncology group at J&J, where he oversaw multiple drug programs. In these roles, Hall was involved in advancing more than 20 cancer drugs from early- to late-stage development. He also worked on biomarker discovery, market segmentation, and companion diagnostics.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.